Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2019 as the company transitions production to a new state-of-the-art facility.
Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine, Stamaril, available in the US through an Expanded Access Investigational New Drug Application (IND).
STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries.
However, it is considered investigational in the US, as it is not a US-licensed product. The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites.
Working closely with the CDC, geographically distributed sites throughout the US are identified for inclusion in the program so patients can have continued access to the yellow fever vaccine.